Abstract
Human serum paraoxonase (PON1) is associated with HDL and inhibits oxidative modification of LDL. PON1 enzymatic activity has been shown to decrease in diabetic patients; however, the effect of PON1 status on long-term outcome has not been reported. In this study, we examined the association between baseline PON1 status and the development of cardiovascular disease (CVD) during 10 years of follow-up in 88 type 2 diabetic patients whose enzymatic activities, concentrations, and genetic polymorphisms of PON1 had been determined. A total of 20 CVD events were recorded during the follow-up period. Using Kaplan–Meier survival curves, we found a significantly increased incidence of CVD in patients with a lower concentration or paraoxonase activity of PON1 than each median value (log-rank 7.460; P < 0.01, and log-rank 4.187; P < 0.05, respectively). By Cox regression analysis, both concentration and paraoxonase activity were significantly associated with the development of CVD, even after correction for gender, age, and preexisting CVD (P < 0.05). Low concentration and enzymatic activity of PON1 may be an independent predictor of cardiovascular events in diabetic patients.
This is a preview of subscription content, log in via an institution to check access.
References
Mackness MI, Arrol S, Abbott C, Durrington PN (1993) Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated praoxonase. Atherosclerosis 104:129–135
Ikeda Y, Suehiro T, Inoue M, Nakauchi Y, Morita T, Arii K, Ito H, Kumon Y, Hashimoto K (1998) Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus. Metabolism 47:598–602
Inoue M, Suehiro T, Nakamura T, Ikeda Y, Kumon Y, Hashimoto K (2000) Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes. Metabolism 49:1400–1405
Mackness B, Mackness MI, Arrol S, Turkie W, Julier K, Abuasha B, Miller JE, Boulton AJM, Durrington PN (1998) Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 139:341–349
Boemi M, Leviev I, Sirolla C, Pieri C, Marra M, James RW (2001) Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis 155:229–235
Lakshman MR, Gottipati CS, Narasimhan SJ, Munoz J, Marmillot P, Nylen ES (2006) Inverse correlation of serum paraoxonase and homocysteine thiolactonase activities and antioxidant capacity of high-density lipoprotein with the severity of cardiovascular disease in persons with type 2 diabetes mellitus. Metabolism 55:1201–1206
McElveen J, Mackness MI, Colley CM, Peard T, Warner S, Walker CH (1986) Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem 32:671–673
Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN (1999) Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 19:330–335
Kim NS, Kang K, Cha MH, Kang B-J, Moon J, Kang BK, Yu B-C, Kim Y-S, Choi SM, Bang O-S (2007) Decreased paraoxonase-1 activity is a risk factor for ischemic stroke in Koreans. Biochem Biophys Res Commun 364:157–162
Can Demirdögen B, Türkanoglu A, Bek S, Sanisoglu Y, Demirkaya S, Vural O, Arınc E, Adalı O (2008) Paraoxonase/arylesterase ratio, PON1 192Q/R polymorphism and PON1 status are associated with increased risk of ischemic stroke. Clin Biochem 41:1–9
Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, Fu X, Shao M, Brennan DM, Ellis SG, Brennan M-L, Allayee H, Lusis AJ, Hazen SL (2008) Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 299:1265–1276
Durrington PN, Mackness B, Mackness MI (2001) Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21:473–480
Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J (2004) Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 363:689–695
Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN (1998) Effect of the human serum paraoxoanse 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 423:57–60
Kotur-Stevuljevic J, Spasic S, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V, Stefanovic A, Vujovic A, Memon L, Kalimanovska-Ostric D (2008) PON1 status is influenced by oxidative stress and inflammation in coronary heart disease patients. Clin Biochem 41:1067–1073
Robertson KS, Hawe E, Miller GJ, Talmud PJ, Humphries SE (2003) Human paraoxonase gene cluster polymorphisms as predictors of coronary heart disease risk in the prospective Northwick Park Heart Study II. Biochim Biophys Acta 1639:203–212
Turban S, Fuentes F, Ferlic L, Brugada R, Gotto AM, Ballantyne CM, Marian AJ (2001) A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin. Atherosclerosis 154:633–640
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ikeda, Y., Inoue, M., Suehiro, T. et al. Low human paraoxonase predicts cardiovascular events in Japanese patients with type 2 diabetes. Acta Diabetol 46, 239–242 (2009). https://doi.org/10.1007/s00592-008-0066-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00592-008-0066-3